Companies with the Most Payment Transactions
Companies ranked by total number of individual payment transactions — the most frequent payers in healthcare.
What This Ranking Tells Us
Transaction volume reveals a different dimension of pharmaceutical industry engagement than dollar amounts. Companies topping this list make millions of individual payments, mostly small — meals, beverages, and educational materials provided during physician interactions. A company with 5 million transactions at $15 average per transaction is engaging with physicians at a fundamentally different scale than a company making 1,000 payments averaging $100,000. High transaction volume indicates broad, frequent touchpoints with the physician community.
What the Data Shows
This ranking covers 100 entries from the CMS Open Payments Public Use Files for Program Year 2024. The top-ranked entry, ABBVIE INC., reports transactions of 1,765,388, while the lowest entry on the list reports 27,347 — a span that captures the full range of pharmaceutical-industry engagement within this category. The aggregate transactions across all 100 ranked entries sums to 13,028,783, and the average is 130,287.83 per entry. Large gaps between the top and bottom of a ranking are normal in Open Payments data: a small number of major pharmaceutical manufacturers, large academic medical centers, or prolific research physicians typically account for a disproportionate share of total reported transfers of value.
Concentration is a key signal in this dataset. The single top entry, ABBVIE INC., represents 13.5% of the transactions aggregated across this ranking. The top 10 entries together represent 45.4% of the total — a useful indicator of how concentrated activity is at the high end of the distribution. In pharmaceutical payment data, high concentration at the top typically reflects a handful of companies with very broad sales forces or extensive patented product portfolios, a few academic medical centers conducting the bulk of industry-sponsored clinical research, or specialist physicians earning royalties from widely-used medical devices they helped invent. A flatter distribution, by contrast, suggests that industry engagement is more evenly spread across the sector.
Every figure on this page is drawn directly from the CMS Open Payments Public Use Files, which pharmaceutical and medical device manufacturers are legally required to report under the Physician Payments Sunshine Act (Section 6002 of the Affordable Care Act). The data covers general payments, research payments, and physician ownership or investment interests. Readers can verify any individual physician or teaching hospital at openpaymentsdata.cms.gov, the official CMS search tool. This ranking surfaces reported financial relationships for transparency purposes only and does not constitute medical advice, a judgment about individual prescribing practices, or evidence of any ethical or legal violation by listed parties. Many large payments fund legitimate research, consulting, and education activities that benefit patient care.
Source: CMS Open Payments, Program Year 2024.
Frequently Asked Questions
Why do some companies have millions of transactions?
The majority of high-volume transactions are food and beverage payments — pharmaceutical sales representatives regularly bring meals to physician offices during detailing visits. A single lunch for a 5-person office is reported as 5 separate transactions. Companies with large sales forces covering many therapeutic areas accumulate millions of these small-value transactions annually.
Do small transactions matter?
Research suggests that even small gifts like meals can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received a single industry-sponsored meal were more likely to prescribe the promoted drug compared to physicians who did not. The aggregate impact of millions of small interactions across the healthcare system is significant.
Explore More Rankings
Read our methodology — how this data is sourced, computed, and verified.
Related
Source: CMS Open Payments Database Industry payments to physicians and teaching hospitals · 2025
How to read this leaderboard
This page is generated dynamically from the latest PlainPharmaWatch snapshot of the CMS Open Payments database. Each row reflects an entity's reported total within the selected ranking dimension — companies, states, physicians, or teaching hospitals — and is recomputed on every request so values track the underlying ETL output rather than a frozen build-time copy. CMS publishes the dataset annually, with corrected snapshots issued mid-cycle when Sunshine-Act disputes change a record set. Anywhere PlainPharmaWatch presents a payment total, the figure is reconcilable to the row-level entries in the source dataset published at openpaymentsdata.cms.gov.
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act, requires applicable manufacturers (drug, device, biological, and medical-supply makers) and applicable group purchasing organizations to report transfers of value made to physicians and teaching hospitals. Reportable categories include consulting fees, food and beverage, travel and lodging, education, gifts, speaking compensation, charitable contributions, royalties or licenses, research-related payments, and ownership or investment interests. Some categories are excluded by statute — payments under specific de minimis thresholds, research-related transfers tied to active clinical trials, and certain product samples — and these exclusions explain why aggregate figures here do not match every alternative pharma-spending measure.
Interpreting rank changes
Rank movement between annual releases reflects two distinct phenomena. Real underlying shifts occur when a manufacturer launches a major product, exits a therapeutic area, restructures its commercial organization, or settles a Department of Justice investigation that alters its marketing approach. Reporting-level shifts occur when CMS revises submission guidelines, when applicable-manufacturer definitions change, or when a previously unreported subsidiary begins consolidated reporting. PlainPharmaWatch does not attempt to attribute rank changes to either cause — that requires looking at the underlying payment-category breakdown on each company's detail page, which itself links back to the raw CMS records.
For physicians ranked individually, year-over-year rank instability is the norm: an active clinical-trial principal investigator may receive the bulk of their reported payments in one program year and far less in adjacent years. A surgeon who licenses a successful medical device may show a sudden royalty-driven spike and then stable lower amounts thereafter. Teaching-hospital rankings tend to be more stable because they reflect institution-wide aggregates across many simultaneously active research programs.
Where to look next
Click any entity name to drill into its full per-entity detail page. Company detail pages decompose total payments by category (consulting, food, royalties, etc.) and show the top recipient physicians and teaching hospitals. State detail pages show payments split between physician and teaching-hospital recipients, plus per-physician averages and recipient counts. The methodology page documents ingestion, normalization, and known limitations end-to-end. For context on the Sunshine Act itself and how the Open Payments dataset compares to alternative pharmaceutical-spending measures (Centers for Medicare and Medicaid Services Open Payments Frequently Asked Questions, the U.S. Food and Drug Administration's drug-approval registers, and academic literature on payment-prescribing correlations), the guides section walks through the relevant regulatory background.